CERO THERAPEUTICS HOLDINGS, INC. (CERO)

OTC Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$0.9M
Cash & Equivalents
$2.8M
Quarterly Burn Rate
$1M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2026-12-31 Phase1 Readout —

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06834282 CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) PHASE1 Recruiting 18

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for CERO.

SEC EDGAR Filings

All SEC filings for CERO THERAPEUTICS HOLDINGS, INC. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.